A Pilot Study of 2% Tofacitinib Cream with Narrowband Ultraviolet B for the Treatment of Facial Vitiligo
August 2019
in “
Journal of The American Academy of Dermatology
”
TLDR Using 2% tofacitinib cream with narrowband ultraviolet B improved facial vitiligo by 70% in patients who didn't respond to previous treatments, with no side effects reported.
In 2019, a pilot study was conducted on 11 patients with facial vitiligo, testing a combination of 2% tofacitinib cream and narrowband ultraviolet B (NB-UVB) therapy for 3 ± 1 months. The patients, who had not responded to previous treatments, showed an average improvement of 70% in their Vitiligo Area Severity Index (VASI) scores. No side effects were reported. The study suggested that topical tofacitinib could be a beneficial addition to vitiligo treatment options, but acknowledged the limitations of a small sample size and lack of controls. The study recommended future controlled studies with larger sample sizes and long-term follow-up.
